New pill aims to ease sickle cell anemia without pain crises
NCT ID NCT07282210
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called SIL-8301 (senicapoc) in 105 adults with sickle cell disease who have low hemoglobin but few pain crises. Participants take the drug or a placebo daily for 24 weeks, along with their usual hydroxyurea. The main goal is to see if the drug raises hemoglobin levels by at least 1 g/dL.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Senicapoc (SIL-8301), a drug taken as tablets
What this could lead to
If it works, this could offer a new daily pill to help manage sickle cell disease by raising hemoglobin levels and reducing complications.
What could go wrong
This is an early Phase 2 trial with only 105 people, so results may not apply to all patients. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••